latest news releases from the newsroom
Investor: Nomination Committee for 2004 Annual General Meeting
STOCKHOLM, Sweden, Oct. 13, 2003 (PRIMEZONE) -- In accordance with the decision made by Investor's (Other OTC:IVSBF) (Other OTC:IVSXF) Annual General Meeting on April 23, 2003, it is hereby announced that the following people, representing the four largest shareholders in Investor AB, will develop a proposal for the composition of the board, under the leadership of the Chairman, for presentation to the Annual General Meeting.
BioXell Expands its Scientific Advisory Board
MILAN, Italy, Oct. 13, 2003 (PRIMEZONE) -- BioXell SpA, today announced the appointment of Professor Karl Erik Andersson and Professor Roger Bouillon to the Company's Scientific Advisory Board (SAB). Karl Erik Andersson is Professor and Head of Clinical Pharmacology at the University of Lund, Sweden. Recognised across the world as a leader in the pharmacology of the urogenital tract, his research has been fundamental in the understanding and treatment of the most significant urogenital diseases.
Two orders of scale-up technology to Pyrosequencing
UPPSALA, Sweden, Oct. 13, 2003 (PRIMEZONE) -- Pyrosequencing AB (OtherOTC:PYRSF) (Stockholm:PYROA) announces that two independent major pharmaceutical companies have each placed one order for microwave scale-up technology. The total value of the orders is over SEK 5,000,000.
Investor Interim Report January -- September 2003
STOCKHOLM, Sweden, Oct. 13, 2003 (PRIMEZONE) -- Investor's (Other OTC:IVSBF) (Other OTC:IVSXF) net asset value on September 30, 2003 amounted to SEK 75,567 m. (SEK 99 per share), compared with SEK 62,869 m. (SEK 82 per share) on December 31, 2002, an increase of 20 percent.
Crucell Announces Third Quarter 2003 Results
LEIDEN, The Netherlands, Oct. 13, 2003 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced its financial results for the third quarter of 2003. Crucell's revenues for the third quarter 2003 were 1.2 million (US$ 1.4 million) compared to 2.0 million (US$ 2.3 million) for the same quarter in 2002. Operating costs for the third quarter of 2003 are 9.8 million (US$ 11.4 million), compared to 9.4 million (US$ 10.9 million) for the same period last year. Net loss for the third quarter was 7.2 million (US$ 8.3 million), compared to 6.5 million (US$ 7.6 million) for the same quarter of last year.
Trintech Group Plc
Capita Selects Trintech's PayWare Merchant to Securely Process all Card Transactions
LONDON and DALLAS, Oct. 13, 2003 (PRIMEZONE) -- Trintech Group Plc (Nasdaq:TTPA) (Prime Standard: TTP), a leading provider of transaction management and payment infrastructure solutions, today announced that Capita Business Services Ltd, part of the Capita Group Plc (LSE:CPI) (Pink Sheets:CTAGF), the largest and fastest growing professional support service organization in the UK, has implemented Trintech's bank-accredited PayWare Merchant solution to process all its card payment transactions for TV Licensing applications.
Brower Piven, A Professional Corporation
Law Offices Of Charles J. Piven, P.A. Announces Class Action Lawsuit Against the Officers and Directors of DDi Corporation -- DDICQ
BALTIMORE, Oct. 10, 2003 (PRIMEZONE) -- Law Offices Of Charles J. Piven, P.A. today announced that a securities class action has been commenced on behalf of shareholders who purchased, converted, exchanged or otherwise acquired the common stock of DDi Corporation (OTCBB:DDICQ) between December 19, 2000 and April 29, 2002, inclusive (the "Class Period").